Nature Reviews Gastroenterology & Hepatology

Article	Citations
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention	1072
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	972
Advances in immunotherapy for hepatocellular carcinoma	764
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma	548
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors	548
Dietary fibre in gastrointestinal health and disease	506
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	447
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments	441
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods	422
Advancing the global public health agenda for NAFLD: a consensus statement	405
The gut microbiome as a modulator of healthy ageing	315
COVID-19 and liver disease: mechanistic and clinical perspectives	278
Evolving therapeutic landscape of advanced hepatocellular carcinoma	272
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications	259
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests	250
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications	248
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2	234
Global epidemiology of cirrhosis — aetiology, trends and predictions	232
The role of goblet cells and mucus in intestinal homeostasis	227
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment	217
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer	216
AHR in the intestinal microenvironment: safeguarding barrier function	207
Therapeutic pipeline in nonalcoholic steatohepatitis	199
Role of liver sinusoidal endothelial cells in liver diseases	196
Current and future colorectal cancer screening strategies	195

Cirrhosis-associated immune dysfunction	193
Cell death in pancreatic cancer: from pathogenesis to therapy	191
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology	191
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer	191
Paracellular permeability and tight junction regulation in gut health and disease	187
The intestinal barrier, an arbitrator turned provocateur in IBD	180
Hepatic inflammatory responses in liver fibrosis	175
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors	173
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity	169
Gastrointestinal biofilms in health and disease	167
Global burden of hepatitis B virus: current status, missed opportunities and a call for action	163
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease	163
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma	160
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	145
Current developments in gastric cancer: from molecular profiling to treatment strategy	142
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders	135
The metabolic nature of inflammatory bowel diseases	133
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment	124
Leveraging diet to engineer the gut microbiome	123
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure	122
Nonalcoholic fatty liver disease: another leap forward	116
Neutrophils as potential therapeutic targets in hepatocellular carcinoma	115
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications	113
Disorders of the enteric nervous system — a holistic view	111
The pancreatic cancer genome revisited	111
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight	109
Breakthroughs in hepatitis C research: from discovery to cure	108
The role of oral bacteria in inflammatory bowel disease	103
COVID-19 and acute pancreatitis: examining the causality	103
Harnessing metabolic dependencies in pancreatic cancers	102
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?	100
Revisiting fibrosis in inflammatory bowel disease: the gut thickens	99
Foundations of gastrointestinal-based drug delivery and future developments	96
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism	95
Hippo signalling in the liver: role in development, regeneration and disease	92
Multiomics to elucidate inflammatory bowel disease risk factors and pathways	91
Gut–liver axis: barriers and functional circuits	90
Recipient factors in faecal microbiota transplantation: one stool does not fit all	90
Intra-pancreatic fat deposition: bringing hidden fat to the fore	88
Bench to bedside — new insights into the pathogenesis of necrotizing enterocolitis	88
Updated epidemiology of gastrointestinal cancers in East Asia	87
Early detection of pancreatic cancer using DNA-based molecular approaches	86
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology	82
Understanding the physiology of human defaecation and disorders of continence and evacuation	82
Macrophages in intestinal homeostasis and inflammatory bowel disease	80
Lifestyle interventions in nonalcoholic fatty liver disease	80
Location is important: differentiation between ileal and colonic Crohn’s disease	79
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	78
Defining comprehensive models of care for NAFLD	78
The promise of the gut microbiome as part of individualized treatment strategies	75

Current and emerging therapies for coeliac disease	74
Circadian clocks in the digestive system	73
Postbiotics — when simplification fails to clarify	73
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease	72
Human biomimetic liver microphysiology systems in drug development and precision medicine	70
The immune microenvironment in gastric adenocarcinoma	70
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	68
The global burden of coeliac disease: opportunities and challenges	66
Gastrointestinal post-acute COVID-19 syndrome	65
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	64
Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation	62
Bacteriophages and their potential for treatment of gastrointestinal diseases	62
Dietary management of adults with IBD — the emerging role of dietary therapy	61
Immunology and immunotherapy of cholangiocarcinoma	60
The scientific basis of combination therapy for chronic hepatitis B functional cure	58
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	57
Regulation and functional roles of chemokines in liver diseases	57
Gut feelings: mechanosensing in the gastrointestinal tract	55
Therapeutic developments in pancreatic cancer	53
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	53
Therapeutic landscape and future direction of metastatic colorectal cancer	51
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation	50
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	50
Optimizing immunotherapy for colorectal cancer	49
The war against pancreatic cancer in 2020 — advances on all fronts	49
IgG4-related diseases of the digestive tract	48
Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract	48
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	47
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease	47
Single-cell RNA sequencing in pancreatic cancer	46
Methanogenic archaea in the human gastrointestinal tract	45
The microbiota and the gut–liver axis in primary sclerosing cholangitis	45
Capturing the environment of the Clostridioides difficile infection cycle	38
Artificial intelligence and automation in endoscopy and surgery	38
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation	35
SARS-CoV-2 vaccination in IBD: more pros than cons	35
Extending treatment eligibility for chronic hepatitis B virus infection	34
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	34
Machine perfusion of the liver: applications in transplantation and beyond	33
Nomenclature of HBV core protein-targeting antivirals	33
Hepatitis C virus elimination: laying the foundation for achieving 2030 targets	32
Mechanisms of pruritus in cholestasis: understanding and treating the itch	32
Exploring liver cancer biology through functional genetic screens	32
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	31
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	29
The gasdermin protein family: emerging roles in gastrointestinal health and disease	27
What are the clinical settings and outcomes of lean NAFLD?	27
Fermented foods and gastrointestinal health: underlying mechanisms	27
Improving IBD outcomes in the era of many treatment options	27
A framework for fibrolamellar carcinoma research and clinical trials	26
Ultra-processed foods and food additives in gut health and disease	26
Gene therapy for liver diseases — progress and challenges	25
Nerves in gastrointestinal cancer: from mechanism to modulations	25
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	25
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis	24
NAFLD, MAFLD and obesity: brothers in arms?	23
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology	23
Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms	22
Modelling intestinal inflammation and infection using ‘mini-gut’ organoids	22
Reply to: Postbiotics — when simplification fails to clarify	21
The maternal gut microbiome in pregnancy: implications for the developing immune system	21
Mycobiota–host immune interactions in IBD: coming out of the shadows	21
Benign liver tumours: understanding molecular physiology to adapt clinical management	21
Deciphering the different phases of preclinical inflammatory bowel disease	21
Human intestinal B cells in inflammatory diseases	21
COVID-19 and liver disease: where are we now?	20
Environmental effects of surgical procedures and strategies for sustainable surgery	20
Inflammatory bowel disease in pregnancy and breastfeeding	20
Precision medicine in IBD: genes, drugs, bugs and omics	20
Another renaissance for bile acid gastrointestinal microbiology	19
Neutrophils: from IBD to the gut microbiota	19
Secretory IgA: controlling the gut microbiota	18
A Roadmap for the Human Gut Cell Atlas	18
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome	18
Advancing on pancreatic cancer	18
Natural history of NAFLD: knowns and unknowns	17
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	17
Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis	17
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	17
Publisher Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	17

Genetics, pathobiology and therapeutic opportunities of polycystic liver disease	17
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	16
Mechanisms and pathophysiology of Barrett oesophagus	16
Environmental enteric dysfunction: gut and microbiota adaptation in pregnancy and infancy	16